药学学报, 2020, 55(4): 554-565
引用本文:
马悦, 魏粉菊, 俞霁, 贾海永, 刘新泳, 展鹏. 基于新靶标的HBV抑制剂研究进展(1):衣壳蛋白抑制剂[J]. 药学学报, 2020, 55(4): 554-565.
MA Yue, WEI Fen-ju, YU Ji, JIA Hai-yong, LIU Xin-yong, ZHAN Peng. Advances in research on HBV inhibitors based on new targets (1): capsid protein inhibitors[J]. Acta Pharmaceutica Sinica, 2020, 55(4): 554-565.

基于新靶标的HBV抑制剂研究进展(1):衣壳蛋白抑制剂
马悦1, 魏粉菊1, 俞霁1, 贾海永2, 刘新泳1, 展鹏1
1. 山东大学药学院药物化学研究所, 化学生物学教育部重点实验室, 山东 济南 250012;
2. 潍坊医学院药学院, 山东 潍坊 261053
摘要:
乙型肝炎病毒(hepatitis B virus,HBV)衣壳蛋白在整个生命周期中起着重要作用,是药物设计的理想靶标。衣壳蛋白抑制剂可以通过抑制HBV的复制,与核苷类药物发挥协同抗病毒作用。本文从药物化学的视角对不同结构类型的HBV衣壳蛋白抑制剂的研究进展进行综述。
关键词:    乙型肝炎病毒      非核苷(酸)类抑制剂      衣壳蛋白抑制剂      药物化学      药物靶点     
Advances in research on HBV inhibitors based on new targets (1): capsid protein inhibitors
MA Yue1, WEI Fen-ju1, YU Ji1, JIA Hai-yong2, LIU Xin-yong1, ZHAN Peng1
1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology(Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;
2. School of Pharmacy, Weifang Medical University, Weifang 261053, China
Abstract:
Hepatitis B virus (HBV) capsid protein plays an important role in the life cycle, thus becoming an ideal target for drug design. Capsid protein inhibitors can exert a synergistic antiviral effect with nucleoside drugs by inhibiting the replication of HBV. This paper reviews the research progress of capsid protein inhibitors with different structural types from the perspective of medicinal chemistry.
Key words:    HBV    non-nucleos(t)ide    capsid protein inhibitors    medicinal chemistry    drug target   
收稿日期: 2019-09-02
DOI: 10.16438/j.0513-4870.2019-0710
基金项目: 国家自然科学基金资助项目(81420108027,81573347);山东省重点研发计划(2017CXGC1401,2019JZZY021011).
通讯作者: 刘新泳,Tel:86-531-88380270,E-mail:xinyongl@sdu.edu.cn;展鹏,E-mail:zhanpeng1982@sdu.edu.cn
Email: xinyongl@sdu.edu.cn;zhanpeng1982@sdu.edu.cn
相关功能
PDF(791KB) Free
打印本文
0
作者相关文章
马悦  在本刊中的所有文章
魏粉菊  在本刊中的所有文章
俞霁  在本刊中的所有文章
贾海永  在本刊中的所有文章
刘新泳  在本刊中的所有文章
展鹏  在本刊中的所有文章

参考文献:
[1] WHO. Fact sheets of HBV[EB/OL]. WHO, 2019,[2020-03-02].https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-b.
[2] Böttcher B, Wynne SA, Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy[J]. Nature, 1997, 386:88-91.
[3] Ceres P, Zlotnick A. Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids[J]. Biochemistry, 2002, 41:11525-11531.
[4] Katen SP, Chirapu SR, Finn MG, et al. Trapping of hepatitis B virus capsid assembly intermediates by phenylpropenamide assembly accelerators[J]. ACS Chem Biol, 2010, 5:1125-1136.
[5] Zhou Z, Hu T, Zhou X, et al. Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms[J]. Sci Rep, 2017, 7:42374.
[6] Nair S, Li L, Francis S, et al. Use of a fluorescent analogue of a HBV core protein-directed drug to interrogate an antiviral mechanism[J]. J Am Chem Soc, 2018, 140:15261-15269.
[7] Schlicksup CJ, Wang JC, Francis S, et al. Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids[J]. ELife, 2018, 7:e31473.
[8] King RW, Ladner SK, Miller TJ, et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine[J]. Antimicrob Agents Chemother, 1998, 42:3179-3186.
[9] Perni RB, Conway SC, Ladner SK, et al. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication[J]. Bioorg Med Chem Lett, 2000, 10:2687-2690.
[10] Dong WL, Liu ZX, Liu XH, et al. Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication[J]. Eur J Med Chem, 2010, 45:1919-1926.
[11] Wang P, Naduthambi D, Mosley RT, et al. Phenylpropenamide derivatives:anti-hepatitis B virus activity of the isomer, SAR and the search for novel analogs[J]. Bioorg Med Chem Lett, 2011, 21:4642-4647.
[12] Katen SP, Tan Z, Chirapu SR, et al. Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure[J]. Structure, 2013, 21:1406-1416.
[13] Zlotnick A, Venkatakrishnan B, Tan ZN, et al. Core protein:a pleiotropic keystone in the HBV lifecycle[J]. Antiviral Res, 2015, 121:82-93.
[14] Liu N, Zhao FB, Jia HY, et al. Non-nucleoside anti-HBV agents:advances in structural optimization and mechanism of action investigations[J]. Med Chem Commun, 2015, 6:521-535.
[15] Weber O, Schlemmer KH, Hartmann E, et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model[J]. Antiviral Res, 2002, 54:69-78.
[16] Deres K, Schröder CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids[J]. Science, 2003, 299:893-896.
[17] Stray SJ, Bourne CR, Punna S, et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly[J]. Proc Natl Acad Sci U S A, 2005, 102:8138-8143.
[18] Bourne CR, Finn MG, Zlotnick A. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1[J]. J Virol, 2006, 80:11055-11061.
[19] Bourne C, Lee S, Venkataiah B, et al. Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle[J]. J Virol, 2008, 82:10262-10270.
[20] Zhu X, Zhao G, Zhou X, et al. 2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly[J]. Bioorg Med Chem Lett, 2010, 20:299-301.
[21] Yang XY, Xu XQ, Guan H, et al. A new series of HAPs as anti-HBV agents targeting at capsid assembly[J]. Bioorg Med Chem Lett, 2014, 24:4247-4249.
[22] Boucle S, Lu X, Bassit L, et al. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors[J]. Bioorg Med Chem Lett, 2017, 27:904-910.
[23] Tu J, Li JJ, Shan ZJ, et al. Exploring the binding mechanism of heteroaryldihydropyrimidines and hepatitis B virus capsid combined 3D-QSAR and molecular dynamics[J]. Antiviral Res, 2017, 137:151-164.
[24] Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets[J]. Hepatol Int, 2011, 5:644-653.
[25] Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly[J]. J Mol Recognit, 2006, 19:542-548.
[26] Wu G, Liu B, Zhang Y, et al. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly[J]. Antimicrob Agents Chemother, 2013, 57:5344-5354.
[27] Klumpp K, Lam AM, Lukacs C, et al. High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein[J]. Proc Natl Acad Sci U S A, 2015, 112:15196-15201.
[28] Zhou X, Li L, Deng P, et al. Characterization of metabolites of GLS4 in humans using ultrahigh-performance liquid chromatography/quadrupole time-of-flight mass spectrometry[J]. Rapid Commun Mass Spectrom, 2013, 27:2483-2492.
[29] Qiu Z, Lin X, Zhou M, et al. Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B virus (HBV) capsid inhibitors[J]. J Med Chem, 2016, 59:7651-7666.
[30] Qiu Z, Lin X, Zhang W, et al. Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors[J]. J Med Chem, 2017, 60:3352-3371.
[31] Li X, Zhou K, He H, et al. Design, synthesis, and evaluation of tetrahydropyrrolo[1,2-c] pyrimidines as capsid assembly inhibitors for HBV treatment[J]. ACS Med Chem Lett, 2017, 8:969-974.
[32] Liu X, Jia H, Zhan P, et al. Preparation of dihydropyrimidine-triazole derivatives useful as anti-HBV agents:CN, 107501257[P]. 2017-12-22.
[33] Ren Q, Liu X, Yan G, et al. 3-((R)-4-(((R)-6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic acid (HEC72702), a novel hepatitis B virus capsid inhibitor based on clinical candidate GLS4[J]. J Med Chem, 2018, 61:1355-1374.
[34] Guo L, Hu T, Hu Y, et al. Preparation of heteroaryldihydropyrimidine derivatives for use in the treatment of hepatitis B virus infection:WO, 2014184328[P]. 2014-11-20.
[35] Guo L, Hu T, Kou B, et al. Preparation of novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus (HBV) infection:CN, 107513073[P]. 2017-12-26.
[36] Ren QY, Liu XC, Huang JZ, et at. 1. Dihydropyrimidine compound and uses of dihydropyrimidine compound in drugs:CN, 109111451[P]. 2019-01-01.
[37] Campagna MR, Liu F, Mao R, et al. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids[J]. J Virol, 2013, 87:6931-6942.
[38] Sari O, Boucle S, Cox BD, et al. Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector[J]. Eur J Med Chem, 2017, 138:407-421.
[39] Wu S, Zhao Q, Zhang P, et al. Discovery and mechanistic study of benzamide derivatives that modulate hepatitis B virus capsid assembly[J]. J Virol, 2017, 91:e00519-17.
[40] Vandyck K, Rombouts G, Stoops B, et al. Synthesis and evaluation of N-phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV)[J]. J Med Chem, 2018, 61:6247-6260.
[41] Wang Z, Fan G, Lu C, et al. Bicyclic nucleocapsid inhibitors and use of same as drugs in treatment of hepatitis B:WO, 2018202155[P]. 2018-11-08.
[42] Lam AM, Espiritu C, Vogel R, et al. Preclinical characterization of NVR 3-778, a first-in-class capsid assembly modulator against hepatitis B virus[J]. Antimicrob Agents Chemother, 2019, 63:e01734-18.
[43] An efficacy, safety, and pharmacokinetics study of JNJ-56136379 in participants with chronic hepatitis B virus infection[EB/OL]. 2019[2019-10-2].https://ClinicalTrials.gov/show/NCT03361956.
[44] In capsid assembly modulator JNJ-56136379 prevents de novo infection of primary human hepatocytes with hepatitis B virus[C]//American Association for the Study of Liver Disease. Boston:The Liver Meeting, 2016.
[45] Kehraus S, König GM, Wright AD, et al. Leucamide A:a new cytotoxic heptapeptide from the Australian sponge Leucettamicroraphis[J]. J Org Chem, 2002, 67:4989-4992.
[46] Chen HJ, Wang WL, Wang GF, et al. Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors[J]. ChemMedChem, 2008, 3:1316-1321.
[47] Yang L, Shi LP, Chen HJ, et al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation[J]. Acta Pharmacol Sin, 2014, 35:410-418.
[48] Jia H, Bai F, Liu N, et al. Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors[J]. Eur J Med Chem, 2016, 123:202-210.
[49] Huber AD, Pineda DL, Liu D, et al. Novel hepatitis B virus capsid-targeting antiviral that aggregates core particles and inhibits nuclear entry of viral cores[J]. ACS Infect Dis, 2019, 5:750-758.
[50] Tang J, Huber AD, Pineda DL, et al. 5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors[J]. Eur J Med Chem, 2019, 164:179-192.
[51] Wang YJ, Lu D, Xu YB, et al. A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation[J]. Antimicrob Agents Chemother, 2015, 59:7061-7072.
[52] Lu D, Liu F, Xing W, et al. Optimization and synthesis of pyridazinone derivatives as novel inhibitors of hepatitis B virus by inducing genome-free capsid formation[J]. ACS Infect Dis, 2017, 3:199-205.
[53] Huang Q, Zong YH, Mercier A, et al. Blockage of HBV virus replication and inhibition of cccDNA establishment by core protein allosteric modifiers (CpAMs)[J]. Hepatology, 2016, 64:937A-938A.
[54] Mani N, Cole AG, Ardzinski A, et al. The HBV capsid inhibitor AB-423 exhibits a dual mode of action and displays additive/synergistic effects in in vitro combination studies[J]. Hepatology, 2016, 64:123A-124A.
[55] Zlotnick A, Ceres P, Singh S, et al. A small molecule inhibits and misdirects assembly of hepatitis B virus capsids[J]. J Virol, 2002, 76:4848-4854.
[56] Lu X, Tran T, Simsek E, et al. The alkylated imino sugar, n-(n-nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture[J]. J Virol, 2003, 77:11933-11940.
[57] Cho MH, Jeong H, Kim YS, et al. 2-Amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor[J]. J Viral Hepat, 2014, 21:843-852.
[58] Pan T, Ding Y, Wu L, et al. Design and synthesis of aminothiazole based hepatitis B virus (HBV) capsid inhibitors[J]. Eur J Med Chem, 2019, 166:480-501.
[59] Pei Y, Wang C, Ben H, et al. Discovery of new hepatitis B virus capsid assembly modulators by an optimal high-throughput cell-based assay[J]. ACS Infect Dis, 2019, 5:778-787.
[60] Kang JA, Kim S, Park M, et al. Ciclopirox inhibits hepatitis B virus secretion by blocking capsid assembly[J]. Nat Commun, 2019, 10:2184.
[61] Seo HW, Seo JP, Cho Y, et al. Cetylpyridinium chloride interaction with the hepatitis B virus core protein inhibits capsid assembly[J]. Virus Res, 2019, 263:102-111.